Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice
Guillaume Darrasse-Jèze, … , Katrina Podsypanina, David Klatzmann
Guillaume Darrasse-Jèze, … , Katrina Podsypanina, David Klatzmann
Published August 3, 2009
Citation Information: J Clin Invest. 2009;119(9):2648-2662. https://doi.org/10.1172/JCI36628.
View: Text | PDF
Research Article Immunology

Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice

  • Text
  • PDF
Abstract

Early responses of Tregs and effector T cells (Teffs) to their first encounter with tumor cells have been poorly characterized. Here we have shown, in both implanted and in situ–induced mouse tumor models, that the appearance of tumor cells is immediately sensed by CD44hi memory Tregs that are specific for self antigens. The rapid response of these Tregs preceded and prevented activation of naive antitumor Teffs. The relative speed of the Treg versus the Teff response within the first 2–4 days determined the outcome of the antitumor immune response: tolerance or rejection. If antitumor memory Teffs were present at the time of tumor emergence, both Tregs and Teffs were recruited and activated with memory kinetics; however, the Tregs were unable to control the Teffs, which eradicated the tumor cells. This balance between effector and regulatory responses did not depend on the number of Tregs and Teffs, but rather on their memory status. Thus, in the natural setting, dominant tolerogenic immunosurveillance by self-specific memory Tregs protects tumors, just as it protects normal tissues. More generally, our results reveal that the timing of Treg and Teff engagement, determined by their memory status, is an important mode of regulation of immune responses.

Authors

Guillaume Darrasse-Jèze, Anne-Sophie Bergot, Aurélie Durgeau, Fabienne Billiard, Benoît L. Salomon, José L. Cohen, Bertrand Bellier, Katrina Podsypanina, David Klatzmann

×

Figure 3

T cell response in mice developing mammary tumors after doxycycline-mediated induction of oncogenes.

Options: View larger image (or click on image) Download as PowerPoint
T cell response in mice developing mammary tumors after doxycycline-medi...
(A) Transgene-expressing cells were analyzed by bioluminescence imaging of the ToMT:IRES:Luc;MTB mice, or control mice lacking the MTB transgene, given doxycycline and BrdU. Representative images show the presence of signal-emitting cells in the mammary gland areas of bitransgenic mice at day 3 of treatment. Representative whole-mount and H&E stainings of mammary glands of the corresponding mice at day 7 after induction demonstrate widespread mammary tumor development in ToMT:IRES:Luc;MTB mice, but not control mice. Scale bar: 100 μm. (B) BrdU incorporation in CD4+CD25+Foxp3+ Tregs and CD4+CD25–Foxp3– and CD8+ T cells from dLNs and ndLNs of ToMT:IRES:Luc;MTB and nLNs of ToMT:IRES:Luc control mice. Numbers within histograms indicate the percentage of cells that incorporated BrdU. n = 4 (dLN), 2 (ndLN), 6 (nLN). Corresponding percentages of BrdU+ cycling T cells are shown graphically. *P < 0.05, **P < 0.01, ***P < 0.005 versus nLN.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts